BIO-key International (BKYI) secures $2.51M and issues 1.24M new warrants in financing
Rhea-AI Filing Summary
BIO-key International entered into a warrant exercise agreement with an existing institutional investor covering the exercise of 618,334 existing warrants to purchase common stock. The exercise price was reduced from $10.20 to $4.06 per share, generating approximately $2.51 million in gross proceeds before fees, which are intended for working capital, general corporate purposes, and potentially partial repayment of a secured note.
In consideration, the investor received 1,236,668 new unregistered warrants with an exercise price of $4.06 per share. These new warrants include a 4.99% beneficial ownership limitation and are exercisable only upon stockholder approval required by Nasdaq rules; they expire five years from any such approval date. BIO-key agreed to seek stockholder approval within 120 days and, if not obtained, to hold additional meetings every 90 days. The company will also file a resale registration statement for the underlying shares, targeting effectiveness within 90 days. Maxim Group LLC acted as exclusive placement agent, earning a 5.0% cash fee on gross proceeds.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 1.01, 3.02, 9.01
3 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 3.02
Unregistered Sales of Equity Securities
Securities
The company sold equity securities in a private placement or other unregistered transaction.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Existing Warrants Exercised: 618,334 shares
Repriced Exercise Price: $4.06 per share
Original Exercise Price: $10.20 per share
+5 more
8 metrics
Existing Warrants Exercised
618,334 shares
Aggregate shares underlying existing warrants exercised by the investor
Repriced Exercise Price
$4.06 per share
Exercise price of existing warrants reduced from $10.20 per share
Original Exercise Price
$10.20 per share
Original exercise price of the existing warrants issued October 28, 2025
New Warrants Issued
1,236,668 warrants
Aggregate shares of common stock underlying the new unregistered warrants
Gross Proceeds
$2.51 million
Approximate gross proceeds received by the company under the agreement
Placement Agent Fee
5.0% of gross proceeds
Cash fee payable to Maxim Group LLC as exclusive placement agent
Beneficial Ownership Cap
4.99%
Maximum beneficial ownership allowed for the investor under new warrants
Meeting Deadline
120 days
Time to convene initial stockholder meeting to seek approval
Key Terms
warrant exercise agreement, beneficial ownership limitation, resale registration statement, Regulation D, +1 more
5 terms
warrant exercise agreement financial
"entered into a warrant exercise agreement with an existing institutional investor"
beneficial ownership limitation regulatory
"include a beneficial ownership limitation that prevents the Investor from beneficially owning"
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.
resale registration statement regulatory
"agreed to file a resale registration statement covering the public resale of the shares"
A resale registration statement is a document filed with regulators that allows existing shareholders to sell their shares to the public. It provides the necessary legal approval and information for these shares to be resold on the market, helping to increase the availability of shares for trading. For investors, it signals that shares held by current owners can be offered for sale, potentially affecting share prices and market liquidity.
Regulation D regulatory
"pursuant to Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D"
Regulation D is a set of rules that govern how companies can raise money from investors without going through the full process required for public stock offerings. It provides simplified options for private placements, making it easier for companies to seek investments from a smaller group of investors. For investors, it offers opportunities to invest in private companies, often with fewer restrictions, but also with different levels of risk and disclosure.
Section 4(a)(2) of the Securities Act regulatory
"transaction exempt from the registration requirements of the Securities Act pursuant to Section 4(a)(2)"
A legal exemption that allows a company to sell securities directly to a limited group of buyers without registering the offering with the Securities and Exchange Commission. Think of it like a private sale among known parties rather than a public auction: it can speed fundraising and reduce disclosure requirements, but it also means less public information, lower liquidity and resale restrictions—factors investors should consider when weighing risk and exit options.
FAQ
What transaction did BIO-key International (BKYI) disclose in this 8-K?
BIO-key entered a warrant exercise agreement with an existing institutional investor, leading to the exercise of 618,334 existing warrants and issuance of 1,236,668 new unregistered warrants at $4.06 per share.
How much cash did BIO-key International (BKYI) receive from the warrant exercise?
BIO-key received approximately $2.51 million in gross proceeds from the exercise of the existing warrants. This amount is before deducting placement agent fees and other offering expenses described in the agreement.
What are the key terms of the new warrants issued by BIO-key (BKYI)?
The new warrants cover 1,236,668 shares at an exercise price of $4.06 per share, include a 4.99% beneficial ownership limitation, become exercisable only after stockholder approval, and terminate five years from any approval date.
How will BIO-key International (BKYI) use the proceeds from this warrant exercise?
BIO-key intends to use the net proceeds for working capital and general corporate purposes, which may include repayment of a portion of the company’s outstanding secured note, according to its disclosure.
What stockholder approvals are required for the new BIO-key (BKYI) warrants?
Exercisability of the new warrants requires stockholder approval under Nasdaq rules. BIO-key agreed to hold a meeting within 120 days, and, if approval is not obtained, to call additional meetings every 90 days until approval.
What compensation did Maxim Group receive in the BIO-key (BKYI) transaction?
Maxim Group LLC acted as exclusive placement agent and is entitled to a 5.0% cash fee on the $2.51 million gross proceeds received by BIO-key under the warrant exercise agreement, pursuant to a placement agency agreement.
AI-generated analysis. How Rhea-AI works. Not financial advice.
